Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI assistant helps GPs spot skin cancer and avoid unnecessary referrals

NCT ID NCT07429123

Knowledge-focused Sponsor: AI Labs Group S.L Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether an artificial intelligence (AI) tool could help primary care doctors more accurately diagnose skin conditions and decide which patients need to see a skin specialist. 131 adults with various skin issues, including possible skin cancer, took part. Doctors took photos of the skin and used the AI as a second opinion. The goal was to see if the tool improved diagnosis and reduced unnecessary specialist visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

131 people

The number who actually took part.

Started

Jun 2022

Finished

Jan 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is drawn from adult patients presenting with dermatological concerns at two primary care centers in the Madrid region: Centro de Salud de Majadahonda and Centro de Salud de Pozuelo. These participants are residents within the catchment areas of these clinics, with Hospital Universitario Puerta de Hierro Majadahonda serving as their reference hospital for specialized dermatology care. The source population consists of individuals in a real-world clinical setting undergoing preliminary assessment by primary care practitioners (PCPs) for potential referral to specialized dermatology services. This diverse cohort is intended to represent a typical population affected by various skin pathologies, specifically including tumoral (benign and malignant), inflammatory, and infectious conditions. Participants are identified and recruited during routine medical visits whenever a skin-related pathology is suspected.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Tumor pathology: * Benign: * Histiocytoma * Seborrheic keratosis * Angiomas * Precancerous: * Actinic keratosis * Suspected malignancy: * Basal cell carcinoma * Squamous cell carcinoma * Pigmented lesions: * Melanocytic nevus * Malignant melanoma * Inflammatory pathology: * Psoriasis * Atopic dermatitis * Urticaria * Hidradenitis suppurativa * Lichen planus * Infectious pathology: * Viral warts * Molluscs * Herpes simplex * Patients aged 18 years or older. * Patients who have signed the informed consent for the study. Exclusion Criteria: * Patients under 18 years of age. * Pregnant patients. * Patients who, in the opinion of the researcher, will not comply with the study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer melanoma neoplasm Skin Abnormalities skin cancer skin disorder skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignancy Melanoma (skin cancer) Skin abnormalities Skin cancer Skin condition

Contacts and locations

Locations

  • Puerta de Hierro Majadahonda University Hospital

    Majadahonda, Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.